Literature DB >> 9815249

Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 molecular pathway.

N A Gomes1, V Barreto-de-Souza, M E Wilson, G A DosReis.   

Abstract

Infection of BALB/c mice with Leishmania chagasi results in progressive increase of parasite burden in spleen, in spite of extensive T cell activation in situ. Explanted splenic CD4+ T cells showed decreased proliferation to anti-CD3, compared with controls, and no response to L. chagasi recombinant antigen Lcr1. Blockade of the negative costimulatory receptor CTLA-4 restored responses to anti-CD3 and induced vigorous responses to Lcr1. Blockade of B7-1, but not B7-2, also enhanced T cell responsiveness. CTLA-4 blockade completely restored activation-induced interleukin-2 secretion and increased interferon-gamma production. The effect, however, was not restricted to Th1 responses, since CTLA-4 blockade also enhanced antigen-induced interleukin-4 secretion. CTLA-4 blockade induced almost complete elimination of parasite burden in splenocyte cultures activated with anti-CD3 or Lcr1. These results indicate that CTLA-4 engagement by B7-1 plays an important role in maintaining unresponsiveness in CD4+ T cells in this model of chronic visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815249     DOI: 10.1086/314520

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

2.  Influence of costimulatory molecules on immune response to Leishmania major by human cells in vitro.

Authors:  C I Brodskyn; G K DeKrey; R G Titus
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  Indoleamine 2,3-dioxygenase (IDO) induced by Leishmania infection of human dendritic cells.

Authors:  M J Donovan; V Tripathi; M A Favila; N S Geraci; M C Lange; W Ballhorn; M A McDowell
Journal:  Parasite Immunol       Date:  2012-10       Impact factor: 2.280

4.  Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Cristina M Lu; Elaine B Brooks; Richard E Fichtl; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 6.  Role of co-stimulation in Leishmaniasis.

Authors:  Rashmi Tuladhar; Gayathri Natarajan; Abhay R Satoskar
Journal:  Int J Biol Sci       Date:  2011-11-01       Impact factor: 6.580

Review 7.  Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis.

Authors:  Rajiv Kumar; Shashi Bhushan Chauhan; Susanna S Ng; Shyam Sundar; Christian R Engwerda
Journal:  Front Immunol       Date:  2017-11-08       Impact factor: 7.561

Review 8.  Unraveling the Role of Immune Checkpoints in Leishmaniasis.

Authors:  Rafael de Freitas E Silva; Esther von Stebut
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

Review 9.  Regulation of immunity during visceral Leishmania infection.

Authors:  Vasco Rodrigues; Anabela Cordeiro-da-Silva; Mireille Laforge; Ricardo Silvestre; Jérôme Estaquier
Journal:  Parasit Vectors       Date:  2016-03-01       Impact factor: 3.876

10.  Leptin regulates Granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB/c Mice.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Jalaja Veronica; Vadloori Bharadwaja; Radheshyam Maurya
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.